These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37781045)

  • 21. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
    Wang D; Yang J
    Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p.
    Song W; Zheng C; Liu M; Xu Y; Qian Y; Zhang Z; Su H; Li X; Wu H; Gong P; Li Y; Fan H
    Mol Ther; 2021 Aug; 29(8):2601-2616. PubMed ID: 33839325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
    Li J; Li Y; Wang D; Liao R; Wu Z
    J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-21-5p promotes sorafenib resistance and hepatocellular carcinoma progression by regulating SIRT7 ubiquitination through USP24.
    Hu Z; Zhao Y; Mang Y; Zhu J; Yu L; Li L; Ran J
    Life Sci; 2023 Jul; 325():121773. PubMed ID: 37187452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
    Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
    Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exosomal miR-93 derived from hepatocellular carcinoma cell promotes the sorafenib resistance of hepatocellular carcinoma through PTEN/PI3K/Akt pathway.
    Bao Y; Xu S; Zhou J; Zhao C; Dai S; Zhang Y; Rao M
    J Biochem Mol Toxicol; 2024 Mar; 38(3):e23666. PubMed ID: 38375688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma.
    Lai HH; Li CW; Hong CC; Sun HY; Chiu CF; Ou DL; Chen PS
    Mol Oncol; 2019 Apr; 13(4):928-945. PubMed ID: 30657254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-25 enhances autophagy and promotes sorafenib resistance of hepatocellular carcinoma via targeting FBXW7.
    Feng X; Zou B; Nan T; Zheng X; Zheng L; Lan J; Chen W; Yu J
    Int J Med Sci; 2022; 19(2):257-266. PubMed ID: 35165511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long intergenic non-protein coding RNA 1273 confers sorafenib resistance in hepatocellular carcinoma via regulation of methyltransferase 3.
    Kong H; Sun J; Zhang W; Zhang H; Li H
    Bioengineered; 2022 Feb; 13(2):3108-3121. PubMed ID: 35037556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
    Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
    Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CircRNA-104718 acts as competing endogenous RNA and promotes hepatocellular carcinoma progression through microRNA-218-5p/TXNDC5 signaling pathway.
    Yu J; Yang M; Zhou B; Luo J; Zhang Z; Zhang W; Yan Z
    Clin Sci (Lond); 2019 Jul; 133(13):1487-1503. PubMed ID: 31278132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
    Awan FM; Naz A; Obaid A; Ikram A; Ali A; Ahmad J; Naveed AK; Janjua HA
    Sci Rep; 2017 Sep; 7(1):11448. PubMed ID: 28904393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long Non-Coding MALAT1 Functions as a Competing Endogenous RNA to Regulate Vimentin Expression by Sponging miR-30a-5p in Hepatocellular Carcinoma.
    Pan Y; Tong S; Cui R; Fan J; Liu C; Lin Y; Tang J; Xie H; Lin P; Zheng T; Yu X
    Cell Physiol Biochem; 2018; 50(1):108-120. PubMed ID: 30278452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CircADSS contributes to hepatocellular carcinoma development by regulating miR-431-5p/TOP2A.
    Gong J; Du C; Sun N; Xiao X; Wu H
    Clin Exp Pharmacol Physiol; 2023 May; 50(5):415-424. PubMed ID: 36786410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells.
    Zhang J; Zhao X; Ma X; Yuan Z; Hu M
    Int J Mol Med; 2020 Nov; 46(5):1794-1804. PubMed ID: 33000204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.